SEC Form 4 · accession 0001000229-17-000027
CORE LABORATORIES N V · CLB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark F Elvig
Officer — VP, Counsel & Secretary
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001000229
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Performance SharesF1 | $0.00 | Feb 14, 2017 | A | 2,400 | A | — | — | Common Shares | 2,400 | 2,400 | D |
Explanation of responses
- F1Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, these awards would vest at the end of a three-year performance period that began on January 1, 2017 and ends on the last NYSE trading day of December 2019 (the "Performance Period"). At the end of the Performance Period, these restricted performance shares will vest only if the Company's return on invested capital (ROIC) is in the top 75th percentile of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. If that criterion is met, the awards shall fully vest and if that criterion is not met, then no shares shall vest and the award shall be forfeited.